STAT

FEBRUARY 1, 2024

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing.

Drug Pricing 288

Drug Pricing Vaccines Communication Drug Development 288

Big Molecule Watch

NOVEMBER 6, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. For drugs selected for the first year of the Program, negotiations will end by August 1, 2024.

Drug Pricing 67

Drug Pricing Biosimilars 67

Safe Biologics

JANUARY 12, 2024

CMS accepted public comments on the Proposed Rule until January 5, 2024. The paper examines the likely negative effects of IRA’s price negotiation provisions, which allow the Centers for Medicare and Medicaid Services to negotiate prices of certain costly drugs, including many biologic medicines. Read it here.

Biosimilars 130

Biosimilars Drug Pricing 130

Drug Channels

APRIL 5, 2024

One important update: In the article below, I suggested that the IRA will make high-list/high-rebate products less attractive to Medicare plans. Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs. Click here to see the original post from January 2024. drug pricing. drug pricing.

Drug Pricing 68

Drug Pricing 68

Safe Biologics

DECEMBER 6, 2023

Learn about ASBM’s recent educational activities surrounding IRA Medicare drug price negotiation, interchangeable biosimilars, and other key policy issues affecting patient access to medicines. Read the full BioSpace article here.

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Proxsys Rx

APRIL 19, 2024

And that is why the one 340B prediction we can make for 2024, unequivocally, is repeated three times in this post’s headline. Which means we may see a lot more states putting manufacturers in their place, in 2024. How covered entities should prepare for 340B changes in 2024 Build a qualified 340B team.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

Proxsys Rx

JANUARY 12, 2024

And that is why the one 340B prediction we can make for 2024, unequivocally, is repeated three times in this post’s headline. Which means we may see a lot more states putting manufacturers in their place, in 2024. How covered entities should prepare for 340B changes in 2024 Build a qualified 340B team.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52